Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 501–600 of 940

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
Chatzidionysiou, K., Liapi, M., Tsakonas, G., Gunnarsson, I., & Catrina, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05420-w · Cited by 24
Isolation of viable antigen-specific CD4 T cells by CD40L surface trapping
Cohen, G. B., Kaur, A., & Johnson, R. P. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.05.002 · Cited by 24
Immunotherapy for metastatic prostate cancer
Laccetti, A. L., & Subudhi, S. K. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000433 · Cited by 24
Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review
Jensen, G. L., Wang, X., Kuempel, J., Palaskas, N. L., Chen, Z., Yu, W., Chen, Y., Mohammad, H., Luo, W., & Chang, J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00687.2024 · Cited by 24
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
Sachpekidis, C., Kopp‐Schneider, A., Pan, L., Papamichail, D., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05137-7 · Cited by 24
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 24
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23
Cytotoxic T-Lymphocyte Antigen-4 +49G/A Polymorphism and Susceptibility to Pancreatic Cancer
Lang, C., Chen, L., & Li, S. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1417 · Cited by 23
CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice
Sabel, M. S., Hess, S. D., Egilmez, N. K., Conway, T. F., Chen, F.-A., & Bankert, R. B. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0668-3 · Cited by 23
α‐Mannosyl‐Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages
Leber, N., Kaps, L., Yang, A., Aslam, M., Giardino, M., Klefenz, A., Choteschovsky, N., Rosigkeit, S., Mostafa, A., Nuhn, L., et al. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201900162 · Cited by 23
Harnessing the potential of multimodal radiotherapy in prostate cancer
Philippou, Y., Sjoberg, H. T., Lamb, A. D. G., Camilleri, P., & Bryant, R. J. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0310-3 · Cited by 24
Immune-Related Adverse Events: Pneumonitis
Jain, A., Shannon, V. R., & Sheshadri, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_6 · Cited by 23
Requirement for CD28 May Not Be Absolute for Collagen-Induced Arthritis: Study with HLA-DQ8 Transgenic Mice
Taneja, V., Taneja, N., Behrens, M. D., Griffiths, M. M., Luthra, H. S., & David, C. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.1118 · Cited by 23
Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer
Feltquate, D., Nordquist, L. T., Eicher, C., Morris, M. J., Smaletz, Ò., Slovin, S. F., Curley, T., Wilton, A. S., Fleisher, M., Heller, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1496 · Cited by 23
Vaccination therapy in prostate cancer
Marrari, A., Iero, M., Pilla, L., Villa, S., Salvioni, R., Valdagni, R., Parmiani, G., & Rivoltini, L. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0233-8 · Cited by 23
Single vs. combination immunotherapeutic strategies for glioma
Chandran, M., Candolfi, M., Shah, D., Mineharu, Y., Yadav, V. N., Koschmann, C. J., Asad, A. S., Lowenstein, P. R., & Castro, M. G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305353 · Cited by 23
Therapeutic approaches to superantigen‐based diseases: a review
Hong‐Geller, E., & Gupta, G. (2003) · Journal of Molecular Recognition · doi:10.1002/jmr.612 · Cited by 23
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
Zhang, Y., Jiang, S., Lv, J., Feng, W., Yu, Y., & Zhao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584450 · Cited by 22
Association of CTLA‐4, TNF alpha and IL 10 polymorphisms with susceptibility to hepatocellular carcinoma
Wang, J., Wang, Z., & Tai-chang, T. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12819 · Cited by 22
Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma
Jangholi, A., Bark, J. M., Kenny, L., Vasani, S. S., Rao, S., Dolcetti, R., & Punyadeera, C. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188784 · Cited by 22
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
Hu, Y. Y., Paris, S., Bertolet, G., Barsoumian, H. B., Wang, Q., SILVA, J. D., Patel, N. B., Nguyen, N., Doss, D. J., Huang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022011 · Cited by 22
Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer
Cao, Y., Yu, K., Zhang, Z., Gu, Y., Gu, Y., Li, W., Zhang, W., Shen, Z., Xu, J., & Qin, J. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1578 · Cited by 22
Surface CD152 (CTLA-4) Expression and Signaling Dictates Longevity of CD28null T Cells
Hoff, H., Knieke, K., Cabail, Z., Hirseland, H., Vratsanos, G., Burmester, G. R., Jorch, G., Nadler, S. G., Bröker, B. M., Hebel, K., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801624 · Cited by 22
Cytotoxic T-Lymphocyte Antigen-4 Polymorphisms and Susceptibility to Ewing's Sarcoma
Yang, S., Wang, C., Zhou, Y., Sun, G., Zhu, D., & Gao, S. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0129 · Cited by 22
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs
Arra, A., Lingel, H., Kuropka, B., Pick, J., Schnoeder, T. M., Fischer, T., Freund, C., Pierau, M., & Brunner-Weinzierl, M. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1273300 · Cited by 23
Perspective: cancer vaccines in the era of immune checkpoint blockade
Cebon, J. S. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9786-z · Cited by 22
Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors
Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy
Vathiotis, I. A., Johnson, J. M., & Argiris, A. E. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102192 · Cited by 23
Candidate nsSNPs that can affect the functions and interactions of cell cycle proteins
Savas, S., Ahmad, M., Shariff, M., Kim, D. Y., & Özçelik, H. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20367 · Cited by 22
Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway
Holsti, M. A., Chitnis, T., Panzo, R. J., Bronson, R. T., Yagita∥, H., Sayegh, M. H., & Tzianabos, A. O. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5774 · Cited by 22
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Eshaq, A. M., Flanagan, T. W., Abbad, A. A. B., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Asheikh, S. A. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010088 · Cited by 23
Future perspectives of prostate cancer therapy.
Gururajan, M., Posadas, E. M., & Chung, L. W. K. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-4683.2012.01.03 · Cited by 21
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer
Pinto, J. A., Raez, L. E., Oliveres, H., & Rolfo, C. D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1610380 · Cited by 22
Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review
Engel, B., Laschtowitz, A., Janik, M. K., Junge, N., Baumann, U., Milkiewicz, P., Taubert, R., & Sebode, M. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104214 · Cited by 23
Immunotherapy treatment outcome prediction in metastatic melanoma through an automated multi-objective delta-radiomics model
Chen, X., Zhou, M., Wang, Z., Si, L., Chang, S., & Zhou, Z. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104916 · Cited by 21
Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer
Kang, S., Tak, J.-H., Cho, J.-H., Lee, H.-J., & Jung, Y. (2010) · Genes & Genomics · doi:10.1007/s13258-010-0139-x · Cited by 21
Foreignness as a matter of degree: the relative immunogenicity of peptide/MHC ligands
van den Berg, H. A., & Rand, D. A. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.07.008 · Cited by 21
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen‐stimulated T cells leading to an increase in cell survival
Vasilevsky, N. A., Ruby, C. E., Hurlin, P. J., & Weinberg, A. D. (2011) · European Journal of Immunology · doi:10.1002/eji.201040449 · Cited by 19
Novel approaches to therapeutic cancer vaccines
Hellström, K. E., & Hellström, I. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.4.517 · Cited by 21
Is the increase in allergic asthma associated with an inborn Th1 maturation or with an environmental Th1 trigger defect?
Wjst, M. (2004) · Allergy · doi:10.1046/j.1398-9995.2003.00374.x · Cited by 21
Poria cocos polysaccharide—functionalized graphene oxide nanosheet induces efficient cancer immunotherapy in mice
Yang, J., Dong, X., Li, B., Chen, T., Yu, B.-S., Wang, X., Dou, X., Peng, B., & Hu, Q. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1050077 · Cited by 20
Immune checkpoints between epithelial-mesenchymal transition and autophagy: A conflicting triangle
Cordani, M., Strippoli, R., Trionfetti, F., Behrooz, A. B., Rumio, C., Velasco, G., Ghavami, S., & Marcucci, F. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216661 · Cited by 20
Exploring combination therapy centered on targeted immunotherapy for advanced hepatocellular carcinoma: a beacon of hope
Wang, Y., Wu, Y., Zhang, H., Wang, J., Song, A., Qiu, H., Yuan, X., Xiong, H., & Zou, Y. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000064 · Cited by 21
Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models
Persson, J., Beyer, I., Yumul, R., Li, Z.-Y., Kiem, H., Roffler, S. R., & Lieber, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022303 · Cited by 20
Immune checkpoint inhibitors and radiotherapy—concept and review of current literature
Thangamathesvaran, L., Shah, R., Verma, R., & Mahmoud, O. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.09 · Cited by 22
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
Passariello, M., Vetrei, C., Sasso, E., Froechlich, G., Gentile, C., D’Alise, A. M., Zambrano, N., Scarselli, E., Nicosia, A., & Lorenzo, C. D. (2020) · Cancers · doi:10.3390/cancers12082204 · Cited by 20
Enhancement of gp120-Specific Immune Responses by Genetic Vaccination with the Human Immunodeficiency Virus Type 1 Envelope Gene Fused to the Gene Coding for Soluble CTLA4
Nayak, B. P., Gangadhara, S., & Jabbar, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10850-10861.2003 · Cited by 20
Combination antibody‐based cancer immunotherapy
Takeda, K., Okumura, K., & Smyth, M. J. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00529.x · Cited by 20
The TRAF1/C5 locus confers risk for familial and severe alopecia areata
Redler, S., Brockschmidt, F. F., Forstbauer, L. M., Giehl, K. A., Herold, C., Eigelshoven, S., Hanneken, S., Weert, J. D., Lutz, G., Wolff, H., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09598.x · Cited by 20
Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.
Hosseinzadeh, F., Mohammadi, S. S., & Nejatollahi, F. (2017) · Europe PMC (PubMed Central) · Cited by 20
Human Nutrition and Genetic Variation
Stover, P. J. (2007) · Food and Nutrition Bulletin · doi:10.1177/15648265070281s109 · Cited by 20
DNA Vaccines Against Cancer
Stan, R., Wolchok, J. D., & Cohen, A. D. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.004 · Cited by 20
Altering immune tolerance therapeutically: the power of negative thinking
Prud’homme, G. J. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0803394 · Cited by 20
Immunotherapy for prostate cancer
Fong, L. H., & Small, E. J. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0026-z · Cited by 20
Immunotherapy in cholangiocarcinoma: From concept to clinical trials
Yao, W., & Gong, W. (2021) · Surgery in Practice and Science · doi:10.1016/j.sipas.2021.100028 · Cited by 19
Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity
Rali, A. S., Ye, H., & Yeh, S. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000434 · Cited by 19
Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal
Lopes-Brás, R., Lopéz‐Presa, D., Esperança‐Martins, M., Melo-Alvim, C., Gallego-Paez, L. M., Costa, L., & Fernandes, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214227 · Cited by 19
The PD-1/PD-L1 Axis in the Biology of MASLD
Pipitone, R. M., Lupo, G., Zito, R., Javed, A., Petta, S., Pennisi, G., & Grimaudo, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073671 · Cited by 20
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
Madan, R. A., Heery, C. R., & Gulley, J. L. (2012) · OncoImmunology · doi:10.4161/onci.20591 · Cited by 19
Analysis of a Previously Identified “Pain-Protective” Haplotype and Individual Polymorphisms in the GCH1 Gene in Africans With HIV-Associated Sensory Neuropathy
Wadley, A. L., Lombard, Z., Cherry, C. L., Price, P., & Kamerman, P. R. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31824bcc17 · Cited by 19
Molecular insights into phytochemicals‐driven break function in tumor microenvironment
Rana, P., Shrama, A., & Mandal, C. C. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13824 · Cited by 20
Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy
Kanagawa, N., Yanagawa, T., Nakagawa, T., Okada, N., & Nakagawa, S. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.85 · Cited by 19
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
Moon, E. K., Langer, C. J., & Albelda, S. Μ. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201702-152fr · Cited by 20
Blimp‐1 is expressed in human and mouse T cell subsets and leads to loss of IL‐2 production and to defective proliferation
Santner‐Nanan, B., Berberich‐Siebelt, F., Xiao, Z. Y., Poser, N., Sennefelder, H., Rauthe, S., Vallabhapurapu, D. S., Berberich, I., Schimpl, A., Kreth, H. W., et al. (2006) · Signal Transduction · doi:10.1002/sita.200500062 · Cited by 19
Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection
O’Neill, D. W., & Bhardwaj, N. (2004) · Humana Press eBooks · doi:10.1385/1-59259-862-5:001 · Cited by 19
BTLA, a new inhibitory B7 family receptor with a TNFR family ligand.
Zeng, C., Wu, T., Yu, Z., Xia, X. P., & Zhao, Y. X. (2005) · PubMed · Cited by 19
Role of CTLA-4 in the Activation of Single- and Double-Positive Thymocytes
Kwon, H., Jun, H., Khil, L., & Yoon, J.-W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6645 · Cited by 19
Delayed Dermatologic Hypersensitivity Reaction Secondary to Ipilimumab
Ludlow, S. P., & Kay, N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000076 · Cited by 18
Cytotoxic T-Lymphocyte Antigen-4 Genetic Variants and Risk of Ewing's Sarcoma
Feng, D., Yang, X., Li, S., Liu, T., Wu, Z., Song, Y., Wang, J., Gao, W., Huang, Q., Huang, W., et al. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0488 · Cited by 18
Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study
Khorshied, M. M., Gouda, H. M., & Khorshid, O. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.820294 · Cited by 18
PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii
Splitt, S. D., Souza, S. P., Valentine, K. M., Castellanos, B. E., Curd, A. B., Hoyer, K. K., & Jensen, K. D. C. (2018) · Infection and Immunity · doi:10.1128/iai.00459-18 · Cited by 19
Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4–Targeted Immunotherapy
Emerson, D. A., Rolig, A. S., & Redmond, W. L. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0338 · Cited by 18
The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma
Oosterhoff, D., Sluijter, B. J. R., Hangalapura, B. N., & de Gruijl, T. D. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_136 · Cited by 18
CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study
Reay, R., Dandara, C., Viljoen, M., & Rheeders, M. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0078 · Cited by 18
Therapeutic potential of immunostimulatory monoclonal antibodies
Gray, J. C., Johnson, P., & Glennie, M. J. (2006) · Clinical Science · doi:10.1042/cs20060024 · Cited by 18
The CCTTT pentanucleotide microsatellite in iNOS promoter influences the clinical outcome in P. falciparum infection
Dhangadamajhi, G., Mohapatra, B. N., Kar, S. K., & Ranjit‬, M. (2009) · Parasitology Research · doi:10.1007/s00436-009-1329-9 · Cited by 18
Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28
Qiu, Y.-H., Sun, Z., Shi, Q., Cheng-hai, S., Chen, Y., Shi, Y., Tao, R. N., Ge, Y., & Zhang, X. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2005.08.022 · Cited by 18
CTLA‐4 regulates the murine immune response to Trypanosoma cruzi infection
Graefe, S. E. B., Jacobs, T., Wächter, U., Bröker, B. M., & Fleischer, B. (2004) · Parasite Immunology · doi:10.1111/j.0141-9838.2004.00679.x · Cited by 18
The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies
Weber, J. S. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232292.06785.a3 · Cited by 18
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
Que, Y., Hu, Y., Hong, D., & Zhang, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002920 · Cited by 18
Artificial Intelligence and Radiomics: Clinical Applications for Patients with Advanced Melanoma Treated with Immunotherapy
McGale, J., Hama, J., Yeh, R., Vercellino, L., Sun, R., Lopci, E., Ammari, S., & Dercle, L. (2023) · Diagnostics · doi:10.3390/diagnostics13193065 · Cited by 17
Exploring the Immunoresponse in Bladder Cancer Immunotherapy
Ruiz-Lorente, I., Gimeno, L., López-Abad, A., Cubillana, P. L., Aparicio, T. F., Egea, L. J. A., Avilés, J. M., Iñiguez, G. D., Martínez-Valls, P. L. G., Server, G., et al. (2024) · Cells · doi:10.3390/cells13231937 · Cited by 18
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
García, J. A., & Dreicer, R. (2011) · PubMed · Cited by 17
Visualization of cell‑cell interaction contacts: Synapses and kinapses
Dustin, M. L. (2011) · Self/Nonself · doi:10.4161/self.2.2.17931 · Cited by 17
Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer
Burotto, M., Singh, N. K., Heery, C. R., Gulley, J. L., & Madan, R. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00351 · Cited by 17
Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction
Duwa, R., Jeong, J., & Yook, S. (2020) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2020.11.015 · Cited by 17
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy
Ishii, H., Afify, S. M., Hassan, G., Salomon, D. S., & Seno, M. (2021) · Cancers · doi:10.3390/cancers13102491 · Cited by 17
Recent insights into the pathogenesis of autoimmune hypophysitis
Frasca, F., Piticchio, T., Moli, R. L., Malaguarnera, R., Campennì, A., Cannavò, S., & Ruggeri, R. M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1974297 · Cited by 17
Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
Wei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19
Advances in the Lung Cancer Immunotherapy Approaches
Padinharayil, H., Alappat, R. R., Joy, L. M., Anilkumar, K. V., Wilson, C. M., George, A., Gopalakrishnan, A. V., Madhyastha, H., Ramesh, T., Sathiyamoorthi, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10111963 · Cited by 18
Forensic and phylogeographic characterisation of mtDNA lineages from Somalia
Mikkelsen, M., Fendt, L., Röck, A. W., Zimmermann, B., Rockenbauer, E., Hansen, A. J., Parson, W., & Morling, N. (2012) · International Journal of Legal Medicine · doi:10.1007/s00414-012-0694-6 · Cited by 17
Transcriptional Activation of the SH2D2A Gene Is Dependent on a Cyclic Adenosine 5′-Monophosphate-Responsive Element in the Proximal SH2D2A Promoter
Dai, K., Johansen, F., Kolltveit, K. M., Aasheim, H., Dembić, Z., Vartdal, F., & Spurkland, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6144 · Cited by 17
T-cell epitope peptide vaccines
Elsawa, S. F., Rodeberg, D. A., & Celis, E. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.5.563 · Cited by 17
CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A
Mukherjee, S., Ahmed, A., & Nandi, D. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1104644 · Cited by 17
Visualization of Cell-Cell Interaction Contacts-Synapses and Kinapses
Dustin, M. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-09789-3_13 · Cited by 17
Geographic stratification of linkage disequilibrium: a worldwide population study in a region of chromosome 22
González‐Neira, A., Calafell, F., Navarro, A., Lao, Ó., Cann, H. M., Comas, D., & Bertranpetit, J. (2004) · Human Genomics · doi:10.1186/1479-7364-1-6-399 · Cited by 17
The role of b7 ligands (cd80 and cd86) in cd152-mediated allograft tolerance: a crosscheck hypothesis
Tsai, M., Ho, H., Chien, H., Ou‐Yang, P., Lee, C., & Lee, P. (2004) · Transplantation · doi:10.1097/01.tp.0000107286.21985.ef · Cited by 17
Programmed Death Ligand 1–Expressing Macrophages and Their Protective Role in the Joint During Arthritis
Wood, M. K., Daoud, A. R., Talor, M. V., Kalinoski, H. M., Hughes, D. M., Jaime, C. M., Hooper, J. E., Won, T., & Čiháková, D. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42749 · Cited by 16
Intralesional and systemic immunotherapy for metastatic melanoma
Luu, C., Khushalani, N. I., & Zager, J. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1233961 · Cited by 16
Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective
Walia, H. K., Sharma, P., Singh, N., & Sharma, S. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00949-1 · Cited by 16

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks